• Jefferies Presentation

  • About Us

    Developing high-value products for patients in niche indications with significant unmet medical need

  • FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy

  • NOW FDA APPROVED

    TARPEYO (budesonide) delayed release capsules

    TARPEYO has been approved only by the US FDA and only for use in the United States. All information concerning TARPEYO on this website is intended solely for residents of the United States.

Vision and Strategy

Calliditas vision is to leverage its interdisciplinary expertise in pharmaceutical product development to identify, develop and commercialize novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Our Pipeline

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Share Price: Sweden

Share Price: US

Interim Report Q1 2022

On May 18, 2022, at 07:00 CEST, Calliditas Therapeutics published its interim report for the first quarter 2022.

Audio cast with teleconference, Q1 2022, May 18, 2022, 14:30 CET